ATE225179T1 - Synergistische zusammensetzung zur behandlung von krebs, welche inulin und ein antikrebsmittel enthält - Google Patents

Synergistische zusammensetzung zur behandlung von krebs, welche inulin und ein antikrebsmittel enthält

Info

Publication number: ATE225179T1
Authority: AT; Austria
Prior art keywords: treatment; cancer; anticancer agent; synergistic composition; cancer containing
Prior art date: 1998-05-18

Application number

AT99924999T

Other languages

English (en)

Inventor

Henryk Taper

Anne Frippiat

Loo Jan Van

Marcel Roberfroid

Original Assignee

Tiense Suikerraffinaderij Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-18

Filing date

1999-05-18

Publication date

2002-10-15

1999-05-18 Application filed by Tiense Suikerraffinaderij Nv filed Critical Tiense Suikerraffinaderij Nv

2002-10-15 Application granted granted Critical

2002-10-15 Publication of ATE225179T1 publication Critical patent/ATE225179T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
201000011510 cancer Diseases 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
229920001202 Inulin Polymers 0.000 title abstract 3
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 title abstract 3
229940029339 inulin Drugs 0.000 title abstract 3
239000002246 antineoplastic agent Substances 0.000 title abstract 2
230000002195 synergetic effect Effects 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 3
230000001399 anti-metabolic effect Effects 0.000 abstract 1
229940041181 antineoplastic drug Drugs 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
-1 inulin Chemical compound 0.000 abstract 1
AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT99924999T 1998-05-18 1999-05-18 Synergistische zusammensetzung zur behandlung von krebs, welche inulin und ein antikrebsmittel enthält ATE225179T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98870113A EP0958825A1 (de)	1998-05-18	1998-05-18	Synergistische Zusammensetzung zur Behandlung von Krebs, welche unverdauliche Kohlenhydrate und eines Antikrebsmittel enthält
PCT/EP1999/003399 WO1999059600A1 (en)	1998-05-18	1999-05-18	Synergistic composition for use in the treatment of cancer

Publications (1)

Publication Number	Publication Date
ATE225179T1 true ATE225179T1 (de)	2002-10-15

Family

ID=8237043

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99924999T ATE225179T1 (de)	1998-05-18	1999-05-18	Synergistische zusammensetzung zur behandlung von krebs, welche inulin und ein antikrebsmittel enthält

Country Status (7)

Country	Link
EP (2)	EP0958825A1 (de)
AT (1)	ATE225179T1 (de)
DE (1)	DE69903283T2 (de)
DK (1)	DK1079840T3 (de)
ES (1)	ES2181446T3 (de)
PT (1)	PT1079840E (de)
WO (1)	WO1999059600A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19836339B4 (de)	1998-08-11	2011-12-22	N.V. Nutricia	Kohlenhydratmischung
EP1125507A1 (de)	2000-02-15	2001-08-22	Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.)	Inulinprodukte mit verbesserten Nahrungseigenschaften
EP1428528A1 (de) *	2002-09-27	2004-06-16	Tiense Suikerraffinaderij N.V.	Synergistische Zusammensetzungen aus Ballaststoffe und NSAID zur Behandlung von Krebs
EP1597978A1 (de)	2004-05-17	2005-11-23	Nutricia N.V.	Synergie von GOS und polyfruktose
US8252769B2 (en)	2004-06-22	2012-08-28	N. V. Nutricia	Intestinal barrier integrity
WO2006002106A2 (en) *	2004-06-22	2006-01-05	Pro-Pharmaceuticals, Inc.	Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
NZ706991A (en)	2010-03-29	2016-08-26	Ferring Bv	A fast dissolving pharmaceutical composition
JO3112B1 (ar) *	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
RU2633640C2 (ru)	2011-09-16	2017-10-16	Ферринг Б.В.	Быстрорастворимая фармацевтическая композиция

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69520528T2 (de) *	1994-06-14	2001-09-27	Raffinerie Tirlemontoise, S.A.	Verwendung einer Zusammensetzung enthaltend Inulin oder Oligofructose als Antikrebsmittel

1998
- 1998-05-18 EP EP98870113A patent/EP0958825A1/de not_active Withdrawn
1999
- 1999-05-18 PT PT99924999T patent/PT1079840E/pt unknown
- 1999-05-18 DE DE69903283T patent/DE69903283T2/de not_active Expired - Lifetime
- 1999-05-18 ES ES99924999T patent/ES2181446T3/es not_active Expired - Lifetime
- 1999-05-18 EP EP99924999A patent/EP1079840B1/de not_active Expired - Lifetime
- 1999-05-18 WO PCT/EP1999/003399 patent/WO1999059600A1/en not_active Ceased
- 1999-05-18 AT AT99924999T patent/ATE225179T1/de not_active IP Right Cessation
- 1999-05-18 DK DK99924999T patent/DK1079840T3/da active

Also Published As

Publication number	Publication date
EP1079840B1 (de)	2002-10-02
ES2181446T3 (es)	2003-02-16
EP1079840A1 (de)	2001-03-07
EP0958825A1 (de)	1999-11-24
PT1079840E (pt)	2002-12-31
DE69903283T2 (de)	2003-02-13
DK1079840T3 (da)	2002-11-04
DE69903283D1 (de)	2002-11-07
WO1999059600A1 (en)	1999-11-25

Similar Documents

Publication	Publication Date	Title
TR200002869T2 (tr)	2000-12-21	İkame edilmiş indolealkonik asitler.
BRPI0411171A (pt)	2006-07-18	derivados de carboidratos de rapamicina, composição farmacêutica, método para o tratamento de uma doença tratável por rapamicina e dispositivo médico
ATE322265T1 (de)	2006-04-15	Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
CY1110426T1 (el)	2015-04-29	Συνδυασμοι dmxaa και αλλων αντικαρκινικων ουσιων
BR0107147A (pt)	2002-06-18	Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
PT693924E (pt)	2004-09-30	Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
ATE534656T1 (de)	2011-12-15	Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
FR2680512B1 (fr)	1995-01-20	Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CY1109695T1 (el)	2014-08-13	Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
DE69127175D1 (de)	1997-09-11	Antisens-Oligonukleotide zur Behandlung von Krebs
DZ2887A1 (fr)	2003-12-15	Dérivés d'azétidine, leur préparation et les médicaments les contenant.
IL162214A0 (en)	2005-11-20	Pyridine derivatives and pharmaceutical compositions containing the same
GEP20043375B (en)	2004-11-25	APRIL-Receptor (BCMA) and Use Thereof
EE04679B1 (et)	2006-08-15	Tuumorivastase toimega kamptotetsiini derivaadid,meetod nende valmistamiseks ja neid hendeid sisaldavad farmatseutilised kompositsioonid
MA26435A1 (fr)	2004-12-20	Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.
AR020662A1 (es)	2002-05-22	Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento.
ATE225179T1 (de)	2002-10-15	Synergistische zusammensetzung zur behandlung von krebs, welche inulin und ein antikrebsmittel enthält
DE60001974D1 (de)	2003-05-08	Derivate von flavonen, xanthonen und kumarinen
PT1358177E (pt)	2006-09-29	Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
DE69907926D1 (de)	2003-06-18	1,2,4-triazol-3-thion verbindungen
TR200200619T2 (tr)	2003-01-21	İkame edilmiş fenoksiasetik asitler.
HUT56849A (en)	1991-10-28	Process for producing antibiotic complexes and chelates and pharmaceutical compositions comprising such active ingredient
DK0624374T3 (da)	2001-01-29	Anvendelse af sulodexid og medicin, som indeholder dette, til behandlingen af diabetisk nephropati
PT1102586E (pt)	2005-02-28	Utilizacao de extractos de ginkgo biloba para a preparacao de um medicamento para o tratamento da esclerose lateral amiotrofica
ATE226065T1 (de)	2002-11-15	Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung

Legal Events

Date	Code	Title	Description
2003-01-15	UEP	Publication of translation of european patent specification
2006-02-15	REN	Ceased due to non-payment of the annual fee